Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans

Drug and Alcohol Dependence

Volumn 157, Issue , 2015, Pages 18-27

  Nugteren van Lonkhuyzen, Johanna J ^a   van Riel, Antoinette J H P ^a   Brunt, Tibor M ^b,c   Hondebrink, Laura ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Clinical; Designer drugs; Legal highs; Research chemicals; Toxicology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 BROMO 2,5 DIMETHOXYPHENETHYLAMINE; 4 FLUOROAMPHETAMINE; 5 (2 AMINOPROPYL)BENZOFURAN; 6 (2 AMINOPROPYL)BENZOFURAN; BENZOFURAN DERIVATIVE; HOMOVERATRYLAMINE; ILLICIT DRUG; NEW DRUG; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG; 2-(4-BROMO-2,5-DIMETHOXYPHENYL)ETHYLAMINE; 4-FLUOROAMPHETAMINE; AMPHETAMINE DERIVATIVE; STREET DRUG;

CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; DRUG ABUSE; DRUG LABELING; HAZARD ASSESSMENT; HEALTH HAZARD; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; REVIEW; SYSTEMATIC REVIEW; TOXICITY TESTING; TOXICOLOGY; ANALOGS AND DERIVATIVES;

AMPHETAMINES; BENZOFURANS; DIMETHOXYPHENYLETHYLAMINE; HUMANS; PSYCHOTROPIC DRUGS; STREET DRUGS;

EID: 84961391436     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.10.011     Document Type: Review

References (111)

1. ACMD, Advisory Council on the Misuse of Drugs 6-APB and 5-APB: A Review of the Evidence of Use and Harm 2013, Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/204808/J_TCDO_report_on_5-6APB_and_NBOMe_compounds.pdf (accessed 06.05.15).
2. ACMD, Advisory Council on the Misuse of Drugs Benzofurans: A Review of the Evidence of Use and Harm 2013, Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261783/Benzofuran_compounds_report.pdf (accessed 06.05.15).
3. Acuña-Castillo C., Villalobos C., Moya P.R., Sáez P., Cassels B.K., Huidobro-Toro J.P. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br. J. Pharmacol. 2002, 136:510-519.
4. Adamowicz P., Zuba D., Byrska B. Fatal intoxication with 3-methyl-N-methylcathinone (3-MMC) and 5-(2-aminopropyl)benzofuran (5-APB). Forensic Sci. Int. 2014, 245:126-132.
5. Al-Abri S., Meier K.H., Colby J.M., Smollin C.G., Benowitz N.L. Cardiogenic shock after use of fluoroamphetamine confirmed with serum and urine levels. Clin. Toxicol. 2014, 52:1292-1295.
6. Ambrose J.B., Bennett H.D., Lee H.S., Josephson S.A. Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphenethylamine ingestion. Neurologist 2010, 16:199-202.
7. Archer R.P., Treble R., Williams K. Reference materials for new psychoactive substances. Drug Test. Anal. 2011, 3:505-514.
8. Archer J.R.H., Dargan P.I., Hudson S., Wood D.M. Analysis of anonymous pooled urine from portable urinals in central London confirms the significant use of novel psychoactive substances. QJM 2012, 106:147-152.
9. Archer J.R.H., Dargan P.I., Lee H.M.D., Hudson S., Wood D.M. Trend analysis of anonymized pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances. Clin. Toxicol. 2014, 52:160-165.
10. Bäckberg M., Lindeman E., Beck O., Jönsson K., Helander A. Do users of novel psychoactive substances take what they think they take? An overview of drug product contents analysed within the Swedish STRIDA project. Abstract presented at the 2015 International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT). Clin. Toxicol. 2015, [Epub ahead of print].
11. Baumann M.H., Clark R.D., Woolverton W.L., Wee S., Blough B.E., Rothman R.B. In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat. J. Pharmacol. Exp. Ther. 2011, 337:218-225.
12. Bilinski P., Kapka-Skrzypczak L., Jablonski P. Determining the scale of designer drugs (DD) abuse and risk to public health in Poland through an epidemiological study in adolescents. Ann. Agric. Environ. Med. 2012, 19:357-364.
13. de Boer D., Gijzels M.J., Bosman I.J., Maes R.A.A. More data about the new psychoactive drug 2C-B. J. Anal. Toxicol. 1999, 23:227-228.
14. de Boer D., dos Reys L.J.A.L., Pylon N., Gijzels M., Bosman I.J., Maes R.A.A. Preliminary results on the urinary excretion of 2C-B (4-bromo-2,5-dimethoxyphenethylamine) and its metabolites in humans. Br. J. Pharmacol. 1999, 127:41P.
15. de Boer D., Bosman I. A new trend in drugs-of-abuse; the 2C-series of phenethylamine designer drugs. Pharm. World Sci. 2004, 26:110-113.
16. Brunt T.M., Koeter M.W., Niesink R.J., van den Brink W. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berlin) 2012, 220:751-762.
17. Carhart-Harris R.L., King L.A., Nutt D.J. A web-based survey on mephedrone. Drug Alcohol Depend. 2011, 118:19-22.
18. Carlsson A. Perspectives on the discovery of central monoaminergic neurotransmission. Ann. Rev. Neurosci. 1987, 10:19-40.
19. Carmo H., Hengstler J.G., de Boer D., Ringel M., Carvalho F., Fernandes E., Remião F., dos Reys L.A., Oesch F., de Lourdes Bastos M. Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369:198-205.
20. Carmo H., Hengstler J.G., de Boer D., Ringel M., Remião F., Carvalho F., Fernandes E., dos Reys L.A., Oesch F., de Lourdes Bastos M. Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase 1 metabolism with hepatocytes of six species including human. Toxicology 2005, 206:75-89.
21. Caudevilla-Gálligo F., Riba J., Ventura M., González D., Farré M., Barbanoj M.J., Bouso J.C. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J. Psychopharmacol. 2012, 26:1026-1035.
22. Chan W.L., Wood D.M., Hudson S., Dargan P.I. Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J. Med. Toxicol. 2013, 9:278-281.
23. Clemente C.G., Chiappini S., Claridge H., Goodair C., Loi B. Deaths involving Benzo fury, United Kingdom 2011-2012. International Centre for Drug Policy 2012, University of London, St George's, Poster presentation. Available at: http://mededlive.co.uk/nps_social/2013/09/deaths-involving-benzo-fury-united-kingdom-2011-2012/ (accessed 06.05.15).
24. Clinical Committee of the Government Delegation for the National Plan on Drugs Emerging Drugs. Report 6 of the Clinical Committee 2011, Ministry of Health, Madrid, Available at: http://www.pnsd.msc.es/Categoria2/publica/pdf/DROGAS_EMERGENTES_ingles_WEB.pdf (accessed 28.01.15).
25. Colado M.I., Williams J.L., Green A.R. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 1995, 115:1281-1289.
26. Cole M.D., Lea C., Oxley N. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): a review of the public domain literature. Sci. Justice 2002, 42:223-224.
27. Dawson P., Opacka-Juffry J., Moffatt J.D., Daniju Y., Dutta N., Ramsey J., Davidson C. The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48:57-63.
28. Dean B.V., Stellpflug S.J., Burnett A.M., Engebretsen K.M. 2C or not 2C: phenethylamine designer drug review. J. Med. Toxicol. 2013, 9:172-178.
29. Dybdal-Hargreaves N.F., Holder N.D., Ottoson P.E., Sweenet M.D., Williams T. Mephedrone: public health risk, mechanism of action, and behavioral effect. Eur. J. Pharmacol. 2013, 714:32-40.
30. Elliott S., Evans J. A 3-year review of new psychoactive substances in casework. Forensic Sci. Int. 2014, 243:55-60.
31. Erowid Experience Vaults - 4-fluoroamphetamine. Available at: (accessed 06.05.15). https://www.erowid.org/experiences/subs/exp_4Fluoroamphetamine.shtml.
32. Erowid Experience Vaults - 6-APB. Available at: (accessed 06.05.15). https://www.erowid.org/experiences/subs/exp_6APB.shtml.
33. Erowid Experience Vaults - 5-APB. Available at: (accessed 06.05.15). https://www.erowid.org/experiences/subs/exp_5APB.shtml.
34. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Monitoring New Drugs 2006, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_40149_EN_Monitoring_new_drugs.pdf (accessed 29.01.15).
35. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Early-warning System on New Psychoactive Substances - Operating Guidelines 2007, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_52451_EN_EWSguidelines2.pdf (accessed 29.01.15).
36. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Annual Report 2010: The State of Drugs Problem in Europe 2010, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_120104_EN_EMCDDA_AR2010_EN.pdf (accessed 28.01.15).
37. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Technical Profile of 4-Fluoroamphetamine 2010, Available at: https://ewsd.wiv-isp.be/Publications%20on%20new%20psychoactive%20substances/4-Fluoramphetamine/4FMP_Tech_Prof_EMCDDA_Mar_2010.pdf (accessed 06.05.15).
38. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) EMCDDA - Europol 2011 Annual Report on the Implementation of Council Decision 2005/387/JHA 2011, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_155113_EN_EMCDDA-Europol%20Annual%20Report%202011_2012_final.pdf (accessed 28.01.15).
39. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Annual Report 2012: The State of Drugs Problem in Europe 2012, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_190854_EN_TDAC12001ENC_pdf (accessed 14.04.15).
40. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) EMCDDA-Europol Joint Report on a New Psychoactive Substance: 5-(2-aminopropyl)indole 2013, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_194430_EN_TDAS13001ENN.pdf (accessed 28.01.15).
41. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) European Drug Report - Trends and Developments 2014, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.pdf (accessed 28.01.15).
42. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) New Psychoactive Substances in Europe - An Update from the EU Early Warning System 2015, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf (accessed 17.04.15).
43. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) European Drug Report. Trends and Developments 2015, Available at: http://www.emcdda.europa.eu/attachements.cfm/att_239505_EN_TDAT15001ENN.pdf (accessed 28.07.15).
44. Flash Eurobarometer 330 Young Attitudes on Drugs. Analytical Report. Survey Conducted by The Gallup Organization, Hungary upon the request of Directorate-General Justice 2011, Available at: http://www.drugsandalcohol.ie/22196/13/Eurobarometer%20401%20Young%20people%20and%20drugs%20-%20full%20report.pdf (accessed 11.08.15).
45. Flash Eurobarometer 401 Young People and Drugs. Report. Conducted by TNS Political & Social at the request of the European Commission, Directorate-General for Justice 2014, Available at: http://www.drugsandalcohol.ie/22196/13/Eurobarometer%20401%20Young%20people%20and%20drugs%20-%20full%20report.pdf (accessed 11.08.15).
46. Giné C.V., Espinosa I.F., Vilamala M.V. New psychoactive substances as adulterants of controlled drugs. a worrying phenomenon?. Drug Test. Anal. 2014, 6:819-824.
47. Giroud C., Augsburger M., Rivier L., Mangin P., Sadeghipour F., Varesio E., Veuthey J.L., Kamalaprija P. 2C-B: a new psychoactive phenylethylamine recently discovered in ecstasy tablets sold on the Swiss black market. J. Anal. Toxicol. 1998, 22:345-354.
48. Glennon R.A., Titeler M., Lyon R.A. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol. Biochem. Behav. 1988, 30:597-601.
49. Goossens F.X., Frijns T., van Hasselt N.E., van Laar M.W. Het Grote Uitgaansonderzoek 2013 2014, Trimbos Institute, Utrecht, The Netherlands, Accessible via: www.trimbos.nl/webwinkel using article number AF1254.
50. Hillebrand J., Olszewski D., Sedefov R. Legal highs on the Internet. Subst. Use. Misuse 2010, 45:330-340.
51. Helander A., Beck O., Hagerkvist R., Hulten P. Identification of novel psychoactive drug use in Sweden based on laboratory analysis - initial experiences from the STRIDA project. Scand. J. Clin. Lab. Invest. 2013, 73:400-406.
52. Helander A., Bäckberg M., Hultén P., Al-Saffar Y., Beck O. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci. Int. 2014, 243:23-29.
53. Ho R.Y., Gerona R., Olson K.R. Clinical course of 4-bromo-2,5-dimethoxyphenylamine (2C-B) intoxication with laboratory confirmation. Abstract presented at the 2013 Annual Meeting of the North American Congress of Clinical Toxicology (NACCT). Clin. Toxicol. 2013, 51:666-667.
54. Hondebrink L., Nugteren-van Lonkhuyzen J.J., van der Gouwe D., Brunt T.M. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the poisons information centre. Drug Alcohol Depend. 2015, 147:109-115.
55. Huang H.H., Bai Y.M. Persistent psychosis after ingestion of a single tablet of '2C-B'. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:293-294.
56. Iversen L., Gibbons S., Treble R., Setola V., Huang X.P., Roth B.L. Neurochemical profiles of some novel psychoactive substances. Eur. J. Pharmacol. 2013, 700:147-151.
57. Jacob P., Shulgin A.T. Structure-activity relationships of the classic hallucinogens and their analogs. Hallucinogens: An Update. NIDA Res. Monograph 146 1994, 74-91. G.C. Lin, R.A. Glennon (Eds.).
58. James D.A., Hill S., Holmes P., Spears R., Thomas S.H.L. Clinical CHARACTERISTICS of 6-(2-Aminopropyl) benzofuran ('Benzo Fury') toxicity reported to the UK National Poisons Information Service. Abstract presented at the 2011 International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT). Clin. Toxicol. 2011, 49:215.
59. Jebadurai J., Schifano F., Deluca P. Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl) benzofuran (benzofury/6-APB) and NRG-2 with review of available evidence-based literature. Human Psychopharmcol. 2013, 28:356-364.
60. Johansen S.S., Hansen T.M. Isomers of fluoroamphetamines detected in forensic cases in Denmark. Int. J. Legal Med. 2012, 126:541-547.
61. Jones A.L., Simpson K.J. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment. Pharmacol. Ther. 1999, 13:129-133.
62. Kanamori T., Nagasawa K., Kuwayama K., Tsujikawa K., Iwata Y.T., Inoue H. Analysis of 4-bromo-2,5-dimethoxyphenethylamine abuser's urine: identification and quantitation of urinary metabolites. J. Forensic Sci. 2013, 58:279-287.
63. Karch S.B. Karch's pathology of drug abuse. Hallucinogens 2002, 287. CRC Press, Boca Raton. S.B. Karch (Ed.).
64. Kerrigan S., Banuelos S., Perrella L., Hardy B. Simultaneous detection of ten psychedelic phenethylamines in urine by gas chromatography-mass spectrometry. J. Anal. Toxicol. 2011, 35:459-469.
65. Kerrigan S., Mellon M.B., Banuelos S., Arndt C. Evaluation of commercial enzyme-linked immunosorbent assays to identify psychedelic phenethylamines. J. Anal. Toxicol. 2011, 35:444-451.
66. Kerrigan S., Mott A., Jatzlau B., Ortiz F., Perrella L., Martin S., Bryand K. Designer psychostimulants in urine by liquid chromatography-tandem mass spectrometry. J. Forensic Sci. 2014, 59:175-183.
67. King L.A. New phenethylamines in Europe. Drug Test. Anal. 2014, 6:808-818.
68. Laskowski L.K., Landry A., Vassallo S.U., Hoffman R.S. Ice water submersion for rapid cooling in severe drug-induced hyperthermia. Clin. Toxicol. 2015, 53:181-184.
69. Linsen F., Koning R.P., van Laar M., Niesink R.J., Koeter M.W., Brunt T.M. 4-fluoroamphetamine in the Netherlands: more than a one-night stand. Addiction 2015, 10.1111/add.12932.
70. Lobos M., Borges Y., Gonzalez E., Cassels B.K. The action of the psychoactive drug 2C-B on isolated rat thoratic aorta. Gen. Pharmacol. 1992, 23:1139-1142.
71. Locatelli C.A., Lonati D., Buscaglia E., Vecchio S., Giampreti A., Petrolini V.M., Chiara F., Aloise M., Corsini E., Papa P., Valli A., Andreoni L., Rimondo C., Seri C., Serpelloni G. Benzofury" poisoning that mimics meningoecephalitis/septicemia. Abstract presented at the 2013 International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT). Clin. Toxicol. 2013, 51:286.
72. Maas A., Wippich C., Madea B., Hess C. Driving under the influence of synthetic phenethylamines: a case series. Int. J. Legal Med. 2015, 129:997-1003.
73. Malpass A., White J.M., Irvine R.J., Somogyi A.A., Bochner F. Acute toxicity of 3 4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark Agouti rats. Pharmacol. Biochem. Behav. 1999, 64:29-34.
74. Marona-Lewicka D., Rhee G.S., Sprague J.E., Nichols D.E. Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur. J. Pharmacol. 1995, 287:105-113.
75. Maxwell J.C. Psychoactive substances - some new, some old: a scan of the situation in the U.S. Drug Alcohol Depend. 2014, 134:71-77.
76. McIntyre I.M., Gary R.D., Trochta A., Stolberg S., Stabley R. Acute 5-(2-aminopropyl)Benzofuran (5-APB) intoxication and fatality: a case report with post-mortem concentrations. J. Anal. Toxicol. 2014, 39:156-159.
77. Miotto K., Striebel J., Cho A.K., Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013, 132:1-12.
78. Monte A.P., Marona-Lewicka D., Cozzi N.V., Nichols D.E. Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4(methylenedioxy)amphetamine. J. Med. Chem. 1993, 36:3700-3706.
79. Montgomery T., Buon C., Eibauer S., Guiry P.J., Keenan A.K., McBean G.J. Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines. Br. J. Pharmacol. 2007, 152:1121-1130.
80. Moya P.R., Berg K.A., Gutiérrez-Hernandez M.A., Sáez-Briones P., Reyes-Parada M., Cassels B.K., Clarke W.P. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT) 2A and 5-HT2C receptors. J. Pharmacol. Exp. Ther. 2007, 321:1054-1061.
81. Mulder-Spijkerboer H.N., Kan A.A., Van Velzen A.G., Van Riel A.J.H.P., Meulenbelt J., De Vries I. Acute vergiftigingen bij mens en dier, NVIC-Jaaroverzicht 2014 2015, UMC Utrecht, Nationaal Vergiftigingen Informatie Centrum. NVIC Rapport 07/2015, Utrecht, Available at: http://www.umcutrecht.nl/nl/Subsites/Nationaal-Vergiftigingen-Informatie-Centrum-(NVIC)/Acute-vergiftigingen (accessed 22.05.15).
82. Nagai F., Nonaka R., Hisashi S., Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 2007, 559:132-137.
83. NDIC, National Drug Intelligence Center Information Bulletin:2C-B (Nexus) Reappears on the Club Drug Scene 2001, National Drug Intelligence Center, Johnstown, PA, Available at: http://www.justice.gov/archive/ndic/pubs0/665/index.htm#Contents (accessed 28.01.15).
84. Nichols D.E. Hallucinogenics. Pharmacol. Ther. 2004, 101:131-181.
85. Páleníček T., Fujáková M., Brunovský M., Horáček J., Gorman I., Balíková M., Rambousek L., Syslová K., Kačer P., Zach P., Bubeníková-Valešová V., Tylš F., Kubešová A., Puskarčíková J., Höschl C. Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. Psychopharmacology (Berlin) 2013, 225:75-93.
86. Patent: "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists" US 7045545 B1. Available at: (accessed 06.05.15). http://www.google.com/patents/US7045545.
87. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
88. Ricaurte G.A., McCann U.D. Recognition and management of complications of new recreational drug use. Lancet 2005, 365:2137-2145.
89. Rickli A., Hoener M.C., Liechti M.E. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur. Neuropsychopharmacol. 2015, 25:365-376.
90. Rickli A., Kopf S., Hoener M.C., Liechti M.E. Pharmacological profile of novel psychoactive benzofurans. Br. J. Pharmacol. 2015, 10.1111/bph.13128.
91. Rohanová M., Páleníček T., Balíková M. Disposition of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and its metabolite 4-bromo-2-hydroxy-5-methoxyphenethylamine in rats after subcutaneous administration. Toxicol. Lett. 2008, 178:29-36.
92. Röhrich J., Becker J., Kaufmann T., Zorntlein S., Urban R. Detection of the synthetic drug 4-fluoroamphetamine (4-FA) in serum and urine. Forensic Sci. Int. 2012, 215:3-7.
93. Rösner P., Quednow B., Girreser U., Junge T. Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs). Forensic Sci. Int. 2005, 148:143-156.
94. Shulgin A.T., Carter M.F. Centrally active phenethylamines. Psychopharmacol. Commun. 1975, 1:93-98.
95. Shulgin A., Shulgin A. PIHKAL: A Chemical Love Story 1991, Transform Press, Berkeley, CA.
96. Simmler L., Buser T., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., Chaboz S., Hoener M., Liechti M.E. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 2013, 168:458-470.
97. Theobald D.S., Maurer H.H. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deanimation of phenethylamine-derived designer drugs (2C-series). Biochem. Pharmacol. 2007, 73:287-297.
98. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., Chu T.Y.Y. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 1994, 47:1151-1156.
99. Uges D.R.A., Steentoft A., Winek C. TIAFT reference blood level list of therapeutic and toxic substances 2004, http://www.gtfch.org/cms/images/stories/Updated_TIAFT_list_202005.pdf.
100. Vazirian M., Jerry J.M., James J., Dale R.M. Bath salts in the emergency department: a survey of emergency clinicians' experience with bath salts-intoxicated patients. J. Addict. Med. 2015, 9:94-98.
101. Verschraagen M., Maes A., Ruiter B., Bosman I.J., Smink B.E., Lusthof K.J. Post-mortem cases involving amphetamine-based drugs in The Netherlands. Comparison with driving under the influence cases. Forensic Sci. Int. 2007, 170:163-170.
102. Villalobos C.A., Bull P., Sáez P., Cassels B.K., Huidobro-Toro J.P. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br. J. Pharmacol. 2004, 141:1167-1174.
103. Wee S., Anderson K.G., Baumann M.H., Rothman R.B., Blough B.E., Woolverton W.L. Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J. Pharmacol. Exp. Ther. 2005, 313:848-854.
104. Welter J., Kavanagh P., Meyer M.R., Maurer H.H. Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSN. Anal. Bioanal. Chem. 2015, 407:1371-1388.
105. Welter J., Brandt S.D., Kavanagh P., Meyer M.R., Maurer H.H. Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MSn techniques. Anal. Bioanal. Chem. 2015, 407:3457-3470.
106. Winstock A.R., Kaar S., Borschmann R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J. Psychopharmacol. 2014, 28:49-54.
107. Wood D.M., Dargan P.I. Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs. J. Med. Toxicol. 2012, 8:300-303.
108. Wood D.M., Measham F., Dargan P.I. 'Our favourite drug': prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. J. Subst. Use 2012, 17:91-97.
109. Wood D.M., Davies S., Puchnarewicz M., Johnston A., Dargan P.I. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur. J. Clin. Pharmacol. 2012, 68:853-856.
110. Zamengo L., Frison G., Bettin C., Sciarrone R. Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products. Toxicol. Lett. 2014, 229:220-228.
111. Zawilska J.B. Methoxetamine-a novel recreational drug with potent hallucinogenic properties. Toxicol. Lett. 2014, 230:402-407.